外来うつ病患者におけるduloxetineの有用性の検討―実臨床下における治療の一環として

Efficacy and Safety of Duloxetine in Outpatients with Major Depressive Disorder in Clinical Practice

抄録

　精神科クリニックにおける外来大うつ病性障害患者57例にduloxetineの投与を行い，4週間の有効性・安全性の検討を行った。投与患者の内訳は新患23例，SSRIからの切替え34例であった。その結果，投与全症例におけるSDSは55.2±8.1から50.5±9.9に有意（p＜0.001）な改善を示した。またCGI-Cを用いて症状の改善を検証した結果，66.0％の症例で改善効果が認められた。これらの薬剤有効性はSSRI無効例からの切替え症例だけに限っても同様に認められた。副作用による脱落例は6例（10.5％）であり，これまで報告された割合よりも若干低かった。Duloxetineは高い効果と忍容性を備えている薬剤であり，大うつ病性障害の治療薬として有用な薬剤であることが確認された。

　The efficacy and safety of duloxetine was investigated in 57 outpatients diagnosed with a major depressive disorder lasting more than 4 weeks in a psychiatric clinic. Of the 57 patients, 23 were newly diagnosed and 34 had switched from SSRI treatments. Efficacy of duloxetine was evaluated using the Self-rating Depression Scale (SDS) and Clinical Global Impression of Change (CGI-C) by comparing the scores before and after treatment.

　SDS score was significantly improved from 55.2±8.1 to 50.5±9.9 (p＜0.001) in all patients. Symptomatic improvement was observed in 66.0% of patients on the CGI-C. Effectiveness was also observed when confined only to the patients who switched from SSRIs. Six patients (10.5%) did not complete the study because of adverse effects；the proportion of dropouts from duloxetine treatment was slightly lower than previously reported.

　Duloxetine is a highly effective, well-tolerated, and useful drug in the treatment of major depressive disorder.